manilatimes1d
The Meet Kevin Pricing Power ETF (PP) to Close
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tidal Financial Group and Plato's Philosophy LLC announce the closure and liquidation of the Meet Kevin Pricing Power ETF (NYSE Arca: PP), effective ...
Pharm Exec5d
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Mind Reading: Fox Sports’ Jay Glazer On The Mental Health Playbook He’s Taking To The Super Bowl
Glazer has been diagnosed with anxiety, depression, ADHD and bipolar disorder. His mental health playbook includes frequent ...
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight
According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...
FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
Zacks.com on MSN6d
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
Investors might want to bet on Supernus Pharmaceuticals (SUPN), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...